Methods for using the obese product to stimulate hematopoietic development
AssigneeIndevus Pharmaceuticals, Inc.
InventorsH. Ralph Snodgrass, Joseph Cioffi, Thomas Joel Zupancic, Alan Wayne Shafer
Life of this patent
Estimating the term…
Loading patent…
AssigneeIndevus Pharmaceuticals, Inc.
InventorsH. Ralph Snodgrass, Joseph Cioffi, Thomas Joel Zupancic, Alan Wayne Shafer
Estimating the term…
The present invention relates to methods for using various forms of a novel receptor expressed by hematopoietic and endothelial cells. An additional variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. Therefore, leptin may be used to stimulate the growth and development of receptor-positive hematopoietic and endothelial cells in vitro and in vivo. In addition, this receptor is selectively expressed in hematopoietic progenitor cells with long-term repopulating potential. Thus, agents that specifically bind to this receptor may be used to identify and isolate progenitor cells for a variety of clinical applications.
A method for promoting angiogenesis or vasculogenesis comprising administering to a subject in need thereof a therapeutic amount of leptin.
A method for treating a subject in need of increased hematopoietic cell function or for enhancing donor bone marrow cell engraftment in bone marrow transplantation, comprising administering to a subject in need thereof a therapeutic amount of leptin and at least IL-3, EPO, and GM-CSF.
Dependencies are inferred from the claim text.